"skipMainNavigation"
Search
Quick Search in Journals
Quick Search anywhere
Advanced Search
Radiology
Menu
Previous
Next
Articles

Gadomer-enhanced MR Imaging in the Detection of Microvascular Obstruction: Alleviation with Nicorandil Therapy

Published Online:Aug 1 2005https://doi.org/10.1148/radiol.2362030847

Abstract

PURPOSE: To evaluate Gadomer-enhanced magnetic resonance (MR) imaging in the quantification of small microvascular obstruction regions and determine if nicroandil alleviates the formation of microvascular obstruction.

MATERIALS AND METHODS: Approval of the institutional committee on animal research was obtained, and this study complied with guidelines for care and use of animals. Rats underwent coronary artery occlusion and reperfusion. After 24 hours, Gadomer-enhanced T1-weighted spin-echo MR imaging was used to define microvascular obstruction in animals in control and nicorandil groups. Sequential MR images obtained at two midventricular levels were acquired to measure microvascular obstruction and ischemically injured regions and monitor diffusive and/or convective transport of Gadomer in microvascular obstruction regions. Two investigators working in consensus and using threshold signal intensity measured differentially enhanced regions. Left-ventricular (LV) end-systolic and end-diastolic MR images obtained at the same two midventricular levels were used to measure regional wall thickening and systolic reduction in LV relative volumes. Agreement and correlation between MR imaging and postmortem data were determined with Bland-Altman and linear regression analyses. Animals were sacrificed 3 minutes after intravenous injection of blue dye.

RESULTS: On Gadomer-enhanced MR images, two differentially enhanced regions were observed in ischemically injured myocardium, namely, the hypoenhanced region and the surrounding hyperenhanced region. Hypoenhanced regions at MR imaging and unstained regions at blue dye administration were identical 3 minutes after administration (17% ± 1 and 17% ± 2; P = .6; r = 0.98). In the control group, Gadomer provided a prolonged imaging window (eg, 6 minutes) for accurately quantifying small microvascular obstruction regions. Microvascular obstruction was observed in all animals in the control group and 27% of animals in the nicorandil group. Microvascular obstruction regions were smaller in the nicorandil group (eg, 3% ± 1) than in the control group (eg, 17% ± 2) (P < .001). Hyper- and hypoenhanced regions were also smaller (eg, 20% ± 2) in rats in the nicorandil group than in those in the control group (37% ± 4, P < .001). Improvement in LV function in the nicorandil group is likely related to alleviation and reduction in infarct size.

CONCLUSION: Gadomer-enhanced MR imaging can be used to quantify small microvascular obstruction regions 24 hours after reperfusion. Intravenous therapy with nicorandil reduces formation of microvascular obstruction regions.

© RSNA, 2005

References

  • 1 Asanuma T, Tanabe K, Ochiai K, et al. Relationship between progressive microvascular damage and intramyocardial hemorrhage in patients with reperfused anterior myocardial infarction. Circulation 1997; 96:448–453.
    Medline Google Scholar
  • 2 Kaul S, Ito H. Microvasculature in acute myocardial ischemia. II. Evolving concepts in pathophysiology, diagnosis, and treatment. Circulation 2004; 109:310–315.
    Google Scholar
  • 3 Piana R, Paik G, Moscucci M, et al. Incidence and treatment of “no-reflow” after percutaneous coronary intervention. Circulation 1994; 89:2514–2518.
    Medline Google Scholar
  • 4 Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50:127–134.
    Medline Google Scholar
  • 5 Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death and crescendo angina. Br Heart J 1985; 53:363–373.
    Medline Google Scholar
  • 6 Erbel R, Heusch G. Coronary microembolization. J Am Coll Cardiol 2000; 36:22–24.
    Medline Google Scholar
  • 7 Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000; 101:570–580.
    Medline Google Scholar
  • 8 Jeremy RW, Links JM, Becker LC. Progressive failure of coronary flow during reperfusion of myocardial infarction: documentation of the no reflow phenomenon with positron emission tomography. J Am Coll Cardiol 1990; 16:695–704.
    Medline Google Scholar
  • 9 Schwitter J, Saeed M, Wendland MF, et al. Influence of severity of myocardial injury on the distribution of macromolecules: extravascular versus intravascular gadolinium-based magnetic resonance contrast agents. J Am Coll Cardiol 1997; 30:1086–1094.
    Medline Google Scholar
  • 10 Bremerich J, Wendland MF, Arheden H, et al. Microvascular injury in reperfused infarcted myocardium: noninvasive assessment with contrast enhanced echoplanar magnetic resonance imaging. J Am Coll Cardiol 1998; 32:787–793.
    Medline Google Scholar
  • 11 Wu KC, Zerhouni E, Judd RM, et al. Prognostic significance of microvascular obstruction magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97:765–772.
    Medline Google Scholar
  • 12 Rochitte CE, Lima JA, Bluemke DA, et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation 1998; 98:1006–1014.
    Medline Google Scholar
  • 13 Gerber BL, Rochitte CE, Melin JA, et al. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation 2000; 101:2734–2741.
    Medline Google Scholar
  • 14 Wu KC, Kim RJ, Bluemke DA, et al. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol 1998; 32:1756–1764.
    Medline Google Scholar
  • 15 Saeed M, van Dijke CF, Mann J, et al. Histologic confirmation of microvascular hyper-permeability to macromolecular MR contrast media in reperfused myocardial infarction. J Magn Reson Imaging 1998; 8:561–567.
    Medline Google Scholar
  • 16 Krombach GA, Wendland MF, Higgins CB, et al. MR imaging of spatial extent of microvascular injury in reperfused ischemically injured rat myocardium: value of blood pool ultrasmall superparamagnetic particles of iron oxide. Radiology 2002; 225:479–486.
    Google Scholar
  • 17 Roberts HC, Saeed M, Roberts TP, et al. Comparison of albumin-(Gd-DTPA)30 and Gd-DTPA-24-cascade-polymer for measurements of normal and abnormal microvascular permeability. J Magn Reson Imaging 1997; 7:331–338.
    Medline Google Scholar
  • 18 Gerber BL, Bluemke DA, Chin BB, et al. Single-vessel coronary artery stenosis: myocardial perfusion imaging with gadomer-17 first-pass MR imaging in a swine model of comparison with gadopentetate dimeglumine. Radiology 2002; 225:104–112.
    Google Scholar
  • 19 Li D, Zheng J, Weinmann HJ. Contrast-enhanced MRI of coronary arteries: comparison of intra- and extravascular contrast agents in swine. Radiology 2001; 218:670–678.
    Google Scholar
  • 20 Misselwitz B, Schmitt-Willich H, Ebert W, et al. Pharmacokinetics of gadomer-17, a new dendritic magnetic resonance contrast agent. MAGMA 2001; 12:128–134.
    Medline Google Scholar
  • 21 Barkhausen J, Herborn C, Bruder O, et al. Contrast-enhanced MR imaging of coronary arteries with gadomer-17 (abstr). J Cardiovasc Magn Reson 2003; 5:5124.
    Google Scholar
  • 22 Taniyama Y, Ito H, Iwakura K, et al. Beneficial effects of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30:1193–1199.
    Medline Google Scholar
  • 23 Hillegass WB, Dean NA, Liao L, et al. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following precutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 2001; 37:1335–1343.
    Medline Google Scholar
  • 24 Fischell TA, Carter AJ, Foster MT, et al. Reversal of “no-reflow” during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998; 45:360–365.
    Medline Google Scholar
  • 25 Taniyama Y, Ito H, Morishita R, et al. Potential of microvascular perfusion with adjunctive pharmacological intervention: its impact on myocardial perfusion and functional outcomes in patients with acute myocardial infarction. Drugs 2001; 61:437–441.
    Medline Google Scholar
  • 26 Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344:1895–1903.
    Medline Google Scholar
  • 27 Sakata Y, Kodama K, Momamura K, et al. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. Am Heart J 1997; 133:616–621.
    Medline Google Scholar
  • 28 Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33:654–660.
    Medline Google Scholar
  • 29 Sugimoto K, Ito H, Iwakura K, et al. Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J 2003; 67:295–300.
    Medline Google Scholar
  • 30 Sato T, Sasaki N, O'Rourke B, et al. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol 2000; 35:514–518.
    Medline Google Scholar
  • 31 Watzinger N, Lund GK, Higgins CB, et al. Noninvasive assessment of the effects of nicorandil on left ventricular volumes and function in reperfused myocardial infarction. Cardiovasc Res 2002; 54:77–84.
    Medline Google Scholar
  • 32 Lund GK, Higgins CB, Wendland MF, et al. Assessment of nicorandil therapy in ischemic myocardial injury by using contrast-enhanced and functional MR imaging. Radiology 2001; 221:676–682.
    Google Scholar
  • 33 Krombach GA, Higgins CB, Chujo M, et al. Blood pool enhanced MRI detects suppression of microvascular permeability in early post-infarction reperfusion after nicorandil therapy. Magn Reson Med 2002; 47:896–902.
    Medline Google Scholar
  • 34 Saeed M, Watzinger N, Krombach G, et al. Left ventricular remodeling after infarction: sequential MR imaging with oral nicorandil therapy in rat model. Radiology 2002; 224:830–837.
    Google Scholar
  • 35 Haager PK, Klues HG, Schmidt M, et al. Effect of nitroglycerin and nicorandil on regional poststenotic quantitative coronary blood flow in coronary artery disease: a combined digital quantitative angiographic and intracoronary Doppler study. J Cardiovasc Pharmacol 1999; 33:126–134.
    Medline Google Scholar
  • 36 Markham A, Plosker GL, Goa KL. Nicorandil: an update review of its use in ischemic heart disease with emphasis on its cardioprotective effects. Drugs 2000; 60:955–974.
    Medline Google Scholar
  • 37 Knight C, Purcell H, Fox K. Potassium channel openers: clinical applications in ischemic heart disease: overview of clinical efficacy of nicorandil. Cardiovasc Drugs Ther 1995; 9(suppl 2):229–236.
    Medline Google Scholar
  • 38 Hale SL, Kloner RA. Effect of early coronary artery perfusion on infarct development in a model of low collateral flow. Cardiovasc Res 1987; 21:668–673.
    Medline Google Scholar
  • 39 Gavin JB, Humphrey SM, Herdson PB. The no-reflow phenomenon in ischemic myocardium. Int Rev Exp Pathol 1983; 25:361–383.
    Medline Google Scholar
  • 40 Schaper W. Experimental infarcts and the microcirculation. In: Hearse DJ, Yellon DM, eds. Therapeutic approaches to myocardial infarct size limitation. New York, NY: Raven, 1984; 79–90.
    Google Scholar
  • 41 Garcia-Dorado D, Theroux P, Solares J, et al. Determinants of hemorrhagic infarcts: histologic observations from experiments involving coronary occlusion, coronary reperfusion, and reocclusion. Am J Pathol 1990; 137:301–311.
    Medline Google Scholar
  • 42 Solal AC, Jaeger P, Bouthier J, et al. Hemodynamic action of nicorandil in chronic congestive heart failure. Am J Cardiol 1989; 63(suppl 21):44J–48J.
    Medline Google Scholar
  • 43 Saeed M, Lund G, Wendland MF, et al. Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction with necrosis specific and extracellular nonspecific contrast media. Circulation 2001; 103:871–876.
    Medline Google Scholar
  • 44 Oh BH, Ono S, Rockman HA, et al. Myocardial hypertrophy in the ischemic zone induced by exercise in rats after coronary reperfusion. Circulation 1993; 87:598–607.
    Medline Google Scholar
  • 45 Weisman HF, Bush DE, Mannisi JA, et al. Global cardiac remodeling after acute myocardial infarction: a study in the rat model. J Am Coll Cardiol 1985; 5:1355–1362.
    Medline Google Scholar
  • 46 Jain M, DerSimonian H, Brenner DA, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001; 103:1920–1927.
    Medline Google Scholar
  • 47 Coltart DJ, Signy M. Acute hemodynamic effects of single-dose nicorandil in coronary artery disease. Am J Cardiol 1989; 63(suppl 21):34J–39J.
    Medline Google Scholar
  • 48 Dauber IM, VanBenthuysen KM, McMurtry IF, et al. Functional coronary microvessel injury evident as increased permeability due to brief ischemia and reperfusion. Circ Res 1990; 66:986–998.
    Medline Google Scholar
  • 49 Inauen W, Payne DK, Kvietys PR, Granger DN. Hypoxia/reoxygenation increases the permeability of endothelial cell monolayers: role of oxygen radicals. Free Radic Biol Med 1990; 9:219–223.
    Medline Google Scholar
  • 50 Kloner RA, Rude RE, Carlson N, et al. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation 1980; 62:945–952.
    Google Scholar
  • 51 Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993; 21:537–545.
    Medline Google Scholar
  • 52 Berdeaux A, Drieu la Rochelle C, Richard V, et al. Differential effects of nitrovasodialtors, K(+)-channel openers and nicorandil on large and small coronary arteries in conscious dogs. J Cardiovasc Pharmacol 1992; 20(suppl 7):S17–S21.
    Google Scholar
  • 53 Liu Y, Sato T, O'Rourke E, Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 1998; 97:2463–2469.
    Medline Google Scholar
  • 54 Wang Y, Hirai K, Ashraf M. Activation of mitochondrial ATP sensitive potassium channel for cardiac protection against ischemic injury is dependent on protein kinase C activity. Circ Res 1999; 85:731–741.
    Medline Google Scholar
  • 55 Horn M, Hugel S, Schroeder M, et al. Mechanisms of the effects of nicorandil in the isolated rat heart during ischemia and reperfusion: a 31P-nuclear magnetic resonance study. J Cardiovasc Magn Reson 2001; 3:349–360.
    Medline Google Scholar

Article History

Published in print: Aug 2005